iSTAR: Phase 1b Trial of Idasanutlin and Selinexor Therapy For Children With Progressive/Relapsed Atypical Teratoid Rhabdoid Tumors, Extra-CNS Malignant Rhabdoid Tumors Or Synchronous/Metachronous Rhabdoid Tumors
Latest Information Update: 02 Apr 2024
At a glance
- Drugs Idasanutlin (Primary) ; Selinexor (Primary)
- Indications Rhabdoid tumour
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 25 Mar 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 Feb 2024 Planned initiation date changed from 1 Feb 2024 to 1 Mar 2024.
- 22 Jan 2024 Planned initiation date changed from 1 Jan 2024 to 1 Feb 2024.